Last reviewed · How we verify
control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program patent landscape — cliff calendar, originator estates, attackable patents
- control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program treatment landscape brief
- control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program treatment updates RSS
Related
- Treatment landscape: control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program patent cliff · control arm in risankizumab phase 3 trials likely psoriasis crohn s disease or ulcerative colitis based on risankizumab s development program CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing